経カテーテル治療：手術および心臓弁市場

世界における経カテーテル治療装置の市場規模は、2018年の40億米ドルから2023年までに80億米ドルへ成長すると予測され、この間は14.8%のCAGR (年間複合成長率) が見込まれています。

当レポートは、世界の経カテーテル治療市場について調査し、市場の定義と概要、各セグメント・地域別による市場分析と予測、競合情勢の分析、および主要企業のプロファイルなどを提供しています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 構造的心臓弁疾患

• 心構造疾患 (SHD)
• 心構造疾患 (SHD) の症状・リスク要因
• 心構造疾患 (SHD) の原因
• 心構造疾患 (SHD) の診断
• 心構造疾患 (SHD) の治療
• 喫煙と心疾患
• 加齢、性別、および心構造疾患 (SHD)
• 現在の課題と将来の方向性

第4章 大動脈弁疾患

• 疾患の概要
• 大動脈弁狭窄症の種類
• 原因、リスク要因、および症状
• 疫学および経済的負担
• 診断
• 治療
• 主な上市・パイプライン製品
• アンメットニーズ
• 現在の課題・将来の発展

第5章 僧帽弁疾患

• 疾患の概要
• 僧帽弁逆流 (MR) の種類
• 原因、リスク要因、および症状
• 疫学および経済的負担
• 診断
• 治療
• 主な上市・パイプライン製品

第6章 市場規模・成長分析

• 市場規模・成長分析
• 市場成長促進要因

第7章 経カテーテル治療装置市場における競合情勢

第8章 経カテーテル治療装置市場における市場戦略

第9章 規制構造：医療機器

第10章 価格・医療費償還：医療機器

第11章 結論：経カテーテル治療装置の展望

第12章 企業プロファイル

第13章 付録：頭字語リスト

第14章 付録B：専門機関

List of Tables

• Summary Table: Global Market for Transcatheter Treatment Devices, by Region, Through 2023
  • Table 1: Scope of Structural Heart Diseases
  • Table 2: Leading Peripheral Vascular Disease Conditions
  • Table 3: Global Prevalence of Peripheral Artery Disease, Through 2021
  • Table 4: Global Incidence Share of Hypertension, by Patient Group, 2017
  • Table 5: Global Prevalence of Angina Pectoris and Stroke, by Survivors, Through 2030
  • Table 6: Global Prevalence of Congestive Heart Failure and Stroke, by Type, Through 2030
  • Table 7: Epidemiology, AAA vs. TAA
  • Table 8: Global vs. U.S. Prevalence of AAA, Through 2023
  • Table 9: BMI Calculation
  • Table 10: BMI Categories Based on Increasing Health Risks
  • Table 11: Trends in Obesity in the World's Population, by Segment, Through 2021
  • Table 12: U.S. Obesity and Severe Obesity vs. General Population, by Segment, Through 2021
  • Table 13: Structural Heart Disease, Management Through Medication
  • Table 14: Structural Heart Valve Disease Treatment Through Surgical Intervention
  • Table 15: Estimated World Population and Annual Growth, by Selected Age Group, Through 2030
  • Table 16: World Population, by Region, Through 2030
  • Table 17: U.S. Population Estimates and Projections, by Age Group, Through 2030
  • Table 18: Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, Through 2020
  • Table 19: European Population Estimates and Projections, by Age Group, Through 2030
  • Table 20: Japanese Population Estimates and Projections, by Age Group, Through 2030
  • Table 21: Aortic Valve Area and Calcification Score, by Stage of Aortic Stenosis
  • Table 22: Global vs. U.S. Prevalence of Aortic Stenosis, Through 2023
  • Table 23: Global vs. U.S. Prevalence of Severe/Symptomatic Aortic Stenosis, Through 2023
  • Table 24: Imaging Techniques for Aortic Stenosis Diagnosis
  • Table 25: Types of Aortic Valve and Repair Techniques
  • Table 26: Advantages and Challenges of TAVI vs. TAVR
  • Table 27: TAVR Access Routes for Aortic Stenosis
  • Table 28: Key Marketed Products in Transcatheter Aortic Valve Treatment
  • Table 29: Key Pipeline/R&D Products in Transcatheter Aortic Valve Treatment
  • Table 30: Mitral Valve Area, by Stage of Mitral Stenosis
  • Table 31: Global vs. U.S. Prevalence of Mitral Regurgitation, Through 2023
  • Table 32: Global vs. U.S. Prevalence of Severe/Symptomatic Mitral Regurgitation, Through 2023
  • Table 33: Imaging Techniques for the Diagnosis of Mitral Valve Disease
  • Table 34: Types of Mitral Valve Repair
  • Table 35: Types of Mitral Valve and Repair Techniques
  • Table 36: TMVI vs. TMVR, Advantages and Challenges
  • Table 37: Key Marketed Products, Transcatheter Mitral Valve Treatment
  • Table 38: Key Pipeline/R&D Products, Transcatheter Mitral Valve Treatment
  • Table 39: Transcatheter Mitral Valve Treatment, Other Less Invasive (MIS) Mitral Valve Technologies
  • Table 40: Global Market for Transcatheter Treatment Devices, by Region, Through 2023
  • Table 41: Global Market for Transcatheter Treatment Devices, by Segment, Through 2023
  • Table 42: Global Market for Transcatheter Treatments, by Procedure (TAVR/TAVI and TMVR), Through 2023
  • Table 43: Global Market for Heart Valves, by Type of Valve, Through 2023
  • Table 44: Global Market for Transcatheter Treatment Devices, by Leading Company, 2017
  • Table 45: Key Strategic Deals in Transcatheter Treatments Market, 2008-2017
  • Table 46: Other Key Strategic Deals (Minority Stakes and Future Options to Acquire) in Transcatheter Treatments Market, 2012-2015
  • Table 47: Differences in Regulatory Approval in the U.S. and Europe
  • Table 48: Transcatheter Aortic Valve Procedures, Billing and Reimbursement, U.S.
  • Table 49: Operations on Aortic Valve, ICD-10 Procedure Code
  • Table 50: Hospital Inpatient Procedures Utilizing MS-DRGs, National Average Reimbursement, CMS
  • Table 51: Trends in Per Capita Real GDP Growth, by Region, 2014-2017
  • Table 52: List of Acronyms

List of Figures

• Summary Figure: Global Market for Transcatheter Treatment Devices, by Region, 2017-2023
  • Figure 1: Global Prevalence of Peripheral Artery Disease, 2000-2021
  • Figure 2: Global Incidence Share of Hypertension, by Patient Group, 2017
  • Figure 3: Global Prevalence of Angina Pectoris and Stroke, by Survivors, 2004-2030
  • Figure 4: Global Prevalence of Congestive Heart Failure and Stroke, by Type, 2004-2030
  • Figure 5: Global vs. U.S. Prevalence of AAA, 2017-2023
  • Figure 6: Trends in Obesity in the World's Population, by Segment, 2012-2021
  • Figure 7: U.S. Obesity and Severe Obesity vs. General Population, by Segment, 2016 and 2021
  • Figure 8: Estimated World Population and Annual Growth, by Selected Age Group, 2000-2030
  • Figure 9: World Population, by Selected Region, 2000-2030
  • Figure 10: U.S. Population Estimates and Projections, by Age Group, 2000-2030
  • Figure 11: Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, 2005-2020
  • Figure 12: European Population Estimates and Projections, by Age Group, 2000-2030
  • Figure 13: Japanese Population Estimates and Projections, by Age Group, 2000-2030
  • Figure 14: Global vs. U.S. Prevalence of Aortic Stenosis, 2017-2023
  • Figure 15: Global vs. U.S. Prevalence of Severe/Symptomatic Aortic Stenosis, 2017-2023
  • Figure 16: Global vs. U.S. Prevalence of Mitral Regurgitation, 2017-2023
  • Figure 17: Global vs. U.S. Prevalence of Severe/Symptomatic Mitral Regurgitation, 2017-2023
  • Figure 18: Global Market for Transcatheter Treatment Devices, by Region, 2017-2023
  • Figure 19: Global Market for Transcatheter Treatment Devices, by Segment, 2017-2023
  • Figure 20: Global Market Share for Transcatheter Mitral Valve Repair, by Disease Condition, 2017
  • Figure 21: Global Market Share for Transcatheter Treatment Devices, by Valve Type, 2017
  • Figure 22: Global Market Share for Transcatheter Aortic Valve Repair Market, by Procedure Approach, 2017
  • Figure 23: Global Market for Transcatheter Treatments, by Procedure (TAVR/TAVI and TMVR), 2017-2023
  • Figure 24: Global Market for Heart Valves, by Type of Valve, 2017-2023
  • Figure 25: Global Heart Valve Repair Market Share, by Surgery Type, 2017
  • Figure 26: Global Market Share for Transcatheter Treatment Devices, by Leading Company, 2017
  • Figure 27: Trends in Per Capita Real GDP Growth, by Region, 2014-2017

Report Highlights:

The global market for transcatheter treatment devices should grow from $4.0 billion in 2018 to $8.0 billion by 2023 at a compound annual growth rate (CAGR) of 14.8% for the period of 2018-2023.

U.S. market for transcatheter treatment devices should grow from $2.3 billion in 2018 to $4.8 billion by 2023 at a CAGR of 15.5% for the period of 2018-2023.

Asia-Pacific market for transcatheter treatment devices should grow from $214.0 million in 2018 to $460.0 million by 2023 at a CAGR of 16.5% for the period of 2018-2023.

Report Scope:

Transcatheter treatment includes procedure types such as TAVR, TAVI, TMVR, and TMVI. Transcatheter procedure approaches include transfemoral, transapical and transaortic procedures. This report is an analytical business tool with the primary purpose of providing a thorough evaluation of the global market for transcatheter treatment for heart valve diseases. The format of this study includes the following -

• Detailed description, including demographics and cost burden, of heart valve diseases (e.g., valvular stenosis and regurgitation) and transcatheter procedure approaches (e.g., transfemoral, transapical and transaortic.)

• Detailed description and analysis of transcatheter treatments devices including TAVR, TAVI, TMVR, and TMVI devices.

• Market characterization, unmet need, market size, and segmentation (by region and treatment).

• Market drivers and restraints.

• Detailed market projections through 2023.

• Competition and market shares.

• Key marketed and pipeline (R&D) products along with information about their regulatory status.

• Strategic landscape (mergers and acquisitions).

• Regulatory structure.

• Pricing and reimbursement.

• Observations and conclusions on the future of transcatheter treatment.

• Profiles of market participants and associations.

Report Includes:

• 28 data tables and 25 additional tables

• An overview of the global market for transcatheter treatment technologies

• Analyses of global market trends, with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023

• Analyses of the market by procedure segments, treatment approaches, and by region

• Detailed market sizing and analyses of the various transcatheter devices and technologies in use or under development

• Description of qualitative and quantitative factors that are driving the global market

• Description of key marketed and pipeline devices and technologies

• Profiles of major companies of the industry including, Abbott Laboratories, Boston Scientific Corp., Medtronic Inc., Vascular Innovations Co. Ltd. And Valcare Inc.

Table of Contents

Chapter 1: Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Information Sources
• Methodology and Information Sources
• Geographic Breakdown
• Analyst's Credentials
• BCC Custom Research
• Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Structural Heart Valve Disease

• Structural Heart Disease
  • Spectrum of Structural Heart Disease
  • Valvular Heart Disease
• Symptoms and Risk Factors of Structural Heart Disease
• Causes of Structural Heart Disease
  • Rheumatic Fever
  • Mitral Valve Prolapse
  • Peripheral Artery Disease
  • Cardiovascular Disease
  • Aortic Aneurysm
  • Obesity
• Diagnosis of Structural Heart Disease
• Treatment of Structural Heart Disease
  • Management Through Medication
  • Surgical Intervention: Heart Valve Repair and Replacement
• Tobacco Smoking and Heart Disease
• Aging, Gender, and Structural Heart Diseases
  • Global Demographics
  • U.S. Demographics
  • European Demographics
  • Japanese Demographics
• Current Challenges and Future Directions

Chapter 4: Aortic Valve Disease

• Disease Overview
• Types of Aortic Stenosis
  • Acquired Aortic Stenosis
  • Congenital Aortic Stenosis
  • Mild and Moderate Aortic Stenosis
  • Severe Aortic Stenosis
  • Asymptomatic Aortic Stenosis
  • Symptomatic Aortic Stenosis
• Causes, Risk Factors, and Symptoms
  • Causes
  • Symptoms
  • Risk Factors
• Epidemiology and Economic Burden
• Diagnosis
  • Standard Doppler Echocardiography
  • Multimodality Imaging
  • Other Techniques
• Treatment
  • Open Surgical Treatment (SAVR)
  • Transcatheter Treatment (TAVR/TAVI)
  • Aortic Valve Repair Versus Aortic Valve Replacement
  • Types of Transcatheter Approaches
  • Open Surgical Repair (SAVR) Versus Transcatheter Treatment (TAVR/TAVI)
  • TAVR and TAVI Complications
• Key Marketed and Pipeline Products
  • Key Marketed Products
  • Key Pipeline/R&D Products
  • Self-expandable Versus Balloon-expandable Devices
• Unmet Need
• Current Challenges and Future Developments

Chapter 5: Mitral Valve Disease

• Disease Overview
• Types of Mitral Regurgitation
  • Degenerative Mitral Regurgitation
  • Functional Mitral Regurgitation
  • Mild and Moderate Mitral Stenosis
  • Severe Mitral Stenosis
  • Asymptomatic Mitral Stenosis
  • Symptomatic Mitral Stenosis
• Causes, Risk Factors, and Symptoms
  • Causes
  • Symptoms
  • Risk Factors
• Epidemiology and Economic Burden
• Diagnosis
  • Standard Echocardiography
  • Multimodality Imaging
  • Other Techniques
• Treatment
  • Open Surgical Treatment (SMVR)
  • Transcatheter Treatment (TMVR and TMVI)
  • Mitral Valve Repair Versus Mitral Valve Replacement
  • Types of Transcatheter Approaches
  • Open Surgery (SMVR) Versus Transcatheter Treatment (TMVR/TMVI)
  • TMVR Complications
• Key Marketed and Pipeline Products
  • Key Marketed Products
  • Key Pipeline/R&D Products
  • Other Less Invasive (MIS) Mitral Valve Technologies
  • Unmet Need
  • Current Challenges and Future Developments

Chapter 6: Market Size and Growth Analysis

• Market Size and Growth Analysis
  • Market Size and Growth Analysis, by Region
  • Market Size and Growth Analysis, by Segment
  • Market Size and Growth Analysis, by Procedure Approach
  • Market Size and Growth Analysis, by Procedure (TAVR/TAVI and TMVR)
  • Heart Valve Market: Traditional Heart Valves (Tissue Heart Valves and Mechanical Heart Valves) Versus Transcatheter Heart Valves
  • Market Growth Drivers and Restraints
• Market Growth Drivers
  • Market Restraints

Chapter 7: Competitive Landscape in Transcatheter Treatment Devices Market

• Competitive Landscape in Transcatheter Treatment Devices Market

Chapter 8: Market Strategies in the Transcatheter Treatment Devices Market

• Market Consolidation in Cardiovascular Devices Market
• Mergers and Acquisitions in Transcatheter Treatment Devices Market
• Recent Mergers and Acquisitions
  • Venus Medtech Acquired Intervalve Inc.
  • LivaNova PLC Acquired Caisson Interventional LLC
  • Boston Scientific Acquired Symetis SA
  • Boston Scientific Acquired Neovasc's Advanced Biological Tissue Manufacturing Assets along with 15% Stake in Neovasc Inc.
  • Edwards Lifesciences Acquired Valtech Cardio Ltd.
  • Venus Medtech Inc. Acquired Transcatheter Technologies' Technology Portfolio
  • Medtronic Acquired Twelve Inc.
  • Abbott Acquired Tendyne Holdings
  • Edwards Lifesciences Acquired CardiAQ Valve Technologies Inc.
  • Micro Interventional Devices Acquired Endovalve Inc.
  • Boston Scientific Acquired Sadra Medical Inc.
  • LoneStar Heart Acquired Cardiopolymers Inc.
  • Abbott Laboratories Acquired Evalve Inc.
  • Medtronic Acquired Ventor Technologies Ltd.
  • The Bracco Group acquired Heart Leaflet Technologies Inc. (HLT)
• Minority Stakes and Future Options to Acquire
  • Abbott Laboratories Secures an Option to Buy Cephea Valve Technologies Inc.
  • Sorin Acquired Minority Stake in HighLife SAS
  • Boston Scientific Secures an Option to Buy MValve Technologies Ltd.
  • Sorin Group Acquired Minority Stake in Cardiosolutions Inc.
• Future Strategic Landscape

Chapter 9: Regulatory Structure: Medical Devices

• Regulatory Background

• Regulatory Systems for Medical Devices, by Region
  • U.S.
  • European Union (EU)
  • Japan

Chapter 10: Pricing and Reimbursement: Medical Devices

• Pricing and Reimbursement Background

• Pricing and Reimbursement for Medical Devices, by Region
  • U.S.
  • Europe
  • Japan

Chapter 11: Conclusions-Outlook for Transcatheter Treatment Devices

• Major Developments Influencing the Market
  • Technological Developments
  • Demographic and Economic Trends
  • Changing Structure of the Healthcare Industry

• Long-term Outlook for Transcatheter Treatments

Chapter 12: Company Profiles

• ABBOTT LABORATORIES
• BIOTRONIK
• BOSTON SCIENTIFIC CORP.
• BRACCO SPA
• BRAILE BIOMEDICA
• CARDIAC DIMENSIONS INC.
• CEPHEA VALVE TECHNOLOGIES INC.
• COLIBRI HEART VALVE LLC
• DIRECT FLOW MEDICAL INC.
• EDWARDS LIFESCIENCES CORP.
• GORMAN CARDIOVASCULAR RESEARCH GROUP
• HANSEN MEDICAL INC. (SUBSIDIARY OF AURIS HEALTH INC.)
• HIGHLIFE SAS
• JENAVALVE TECHNOLOGY INC.
• LABORATORIES INVALV
• LIVANOVA PLC
• LONESTAR HEART INC.
• MEDTRONIC INC.
• MICRO INTERVENTIONAL DEVICES INC.
• MICROPORT SCIENTIFIC
• MITRAGEN INC.
• MITRALIX LTD.
• MITRALTECH LTD.
• MITRASSIST LTD.
• MITRICARES SAS
• MITRAL HEAL LTD.
• MITRALIGN INC.
• MVRX INC.
• NAKOSTECH SARL
• NAVIGATE CARDIAC STRUCTURES INC.
• NEOVASC INC.
• NEW VALVE TECHNOLOGY (NVT) AG
• SINO MEDICAL SCIENCE TECHNOLOGY INC.
• ST. JUDE MEDICAL INC. (SUBSIDIARY OF ABBOTT LABORATORIES)
• TAU-PNU MEDICAL CO. LTD.
• THUBRIKAR AORTIC VALVE INC.
• TRANSCATHETER TECHNOLOGIES GMBH
• TRANSMURAL SYSTEMS
• VASCULAR INNOVATIONS CO. LTD.
• VALCARE INC.
• VALVEXCHANGE INC.
• VENUS MEDTECH INC.

Chapter 13: Appendix A: List of Acronyms

Chapter 14: Appendix B: Professional Organizations

• American Heart Association
• Center for Drug Evaluation and Research (CDER)
• Center for Devices and Radiological Health (CDRH)
• Centers for Medicare & Medicaid Services (CMS)
• European Databank for Medical Devices (EUDAMED)
• Food and Drug Administration (FDA or USFDA)
• Hormone Foundation
• International Diabetes Federation (IDF)
• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
• Network for Excellence in Health Innovation (NEHI)
• National Center for Biotechnology Information (NCBI)
• National Institute of Aging (NIA)
• Pharmaceuticals and Medical Devices Agency (PMDA)
• World Cancer Research Fund International
• World Health Organization (WHO)